English

Foamix Pharmaceuticals Ltd.

EDGAR

Annual report (10-K) · filed 2020-03-12

56 filing records in this dataset, filed from 2014-08-13 to 2020-03-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

135 thousand USD

2019 Q4 · USD

Exact inputs and evidence

Revenue: 135000 USD Source

Operating margin

-27,726.67%

2019 Q4 · %

Exact inputs and evidence

Operating Income: -37431000 USD Source
Revenue: 135000 USD Source

Operating cash flow

-22.2 million USD

2019 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -73394000 USD Source
Operating Cash Flow: -51148000 USD Source

Free cash flow

-22.4 million USD

2019 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -73394000 USD Source
Operating Cash Flow: -51148000 USD Source
Capital Expenditure: 1058000 USD Source
Capital Expenditure: 861000 USD Source

Cash and cash equivalents: 43.8 million USD 2019-12-31 Source
Exact value

43759000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 61.6 million shares 2019-12-31 Source
Exact value

61580544 shares

Reported share-count change

13.30% · 7.23 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

54351140 shares · 2018-12-31· Source
61580544 shares · 2019-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

443 thousand USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Revenue: 308000 USD · 2019-01-01 – 2019-03-31 Source
Revenue: 308000 USD · 2019-01-01 – 2019-06-30 Source
Revenue: 308000 USD · 2019-01-01 – 2019-03-31 Source
Revenue: 308000 USD · 2019-01-01 – 2019-09-30 Source
Revenue: 308000 USD · 2019-01-01 – 2019-06-30 Source
Revenue: 135000 USD · 2019-10-01 – 2019-12-31 Source

Net income

-95.2 million USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Net income: -15204000 USD · 2019-01-01 – 2019-03-31 Source
Net income: -18993000 USD · 2019-04-01 – 2019-06-30 Source
Net income: -23161000 USD · 2019-07-01 – 2019-09-30 Source
Net income: -95178000 USD · 2019-01-01 – 2019-12-31 Source
Net income: -57358000 USD · 2019-01-01 – 2019-09-30 Source

Operating cash flow

-73.4 million USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Operating cash flow: -16642000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -29361000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -16642000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -51148000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -29361000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -73394000 USD · 2019-01-01 – 2019-12-31 Source
Operating cash flow: -51148000 USD · 2019-01-01 – 2019-09-30 Source

Capital expenditure

1.06 million USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Capital expenditure: 138000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 454000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 138000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 861000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 454000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 1058000 USD · 2019-01-01 – 2019-12-31 Source
Capital expenditure: 861000 USD · 2019-01-01 – 2019-09-30 Source

Free cash flow

-74.5 million USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Operating cash flow: -16642000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -29361000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -16642000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -51148000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -29361000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -73394000 USD · 2019-01-01 – 2019-12-31 Source
Operating cash flow: -51148000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 138000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 454000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 138000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 861000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 454000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 1058000 USD · 2019-01-01 – 2019-12-31 Source
Capital expenditure: 861000 USD · 2019-01-01 – 2019-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-03-12.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2019-12-31
Operating income: 8 of 11 periods available· newest 2019-12-31
Net income: 8 of 11 periods available· newest 2019-12-31
Operating cash flow: 8 of 11 periods available· newest 2019-12-31
Capital expenditure: 7 of 11 periods available· newest 2019-12-31
Total assets: 7 of 11 periods available· newest 2019-12-31
Total liabilities: 7 of 11 periods available· newest 2019-12-31
Current assets: 7 of 11 periods available· newest 2019-12-31
Current liabilities: 7 of 11 periods available· newest 2019-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2019-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-87.7%

Prior period

USD 3.6 million

2018-01-01 – 2018-12-31
Current period

USD 443,000

2019-01-01 – 2019-12-31

Exact inputs and evidence

443000 − 3595000 = -3152000 USD

3595000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
443000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Year-over-year change in Revenue: -3152000 USD Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 443000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#119079 Filing: 000117891320000792 Input fundies:Revenue: 3595000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#118078 Filing: 000117891320000792
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 21.02 million

Prior period

−USD 74.16 million

2018-01-01 – 2018-12-31
Current period

−USD 95.18 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-95178000 − -74163000 = -21015000 USD

-74163000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-95178000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Year-over-year change in Net income: -21015000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -95178000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#244666 Filing: 000117891320000792 Input fundies:NetIncome: -74163000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#244537 Filing: 000117891320000792
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 4.73 million

Prior period

−USD 68.66 million

2018-01-01 – 2018-12-31
Current period

−USD 73.39 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-73394000 − -68664000 = -4730000 USD

-68664000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-73394000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Year-over-year change in Operating cash flow: -4730000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -73394000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#228120 Filing: 000117891320000792 Input fundies:OperatingCashFlow: -68664000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#227933 Filing: 000117891320000792
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+86.6%

Prior period

USD 567,000

2018-01-01 – 2018-12-31
Current period

USD 1.06 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

1058000 − 567000 = 491000 USD

567000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
1058000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Year-over-year change in Capital expenditure: 491000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1058000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133872 Filing: 000117891320000792 Input fundies:CapitalExpenditure: 567000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133688 Filing: 000117891320000792
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 443,000 100% of revenue
Cost of revenue USD 0 0% of revenue
Operating expenses USD 96.32 million 21,742% of revenue
Operating income −USD 95.87 million −21,642% of revenue
Tax, interest and other Derived −USD 695,000 −157% of revenue
Net income −USD 95.18 million −21,485% of revenue

Cash

Operating cash flow −USD 73.39 million −16,567% of revenue
Capital expenditure USD 1.06 million 239% of revenue
Free cash flow Derived −USD 74.45 million −16,806% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Operating loss: operating costs were 244% of revenue.
2013 Operating loss: operating costs were 197% of revenue.
2014 Operating loss: operating costs were 130% of revenue.
2015 Operating loss: operating costs were 2,094% of revenue.
2016 Operating loss: operating costs were 636% of revenue.
2017 Operating loss: operating costs were 1,888% of revenue.
2018 Operating loss: operating costs were 2,183% of revenue.
2019 Operating loss: operating costs were 21,742% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2012-01-01 – 2012-12-31	1086000	2646000 Derived	-1560000	609000 Derived	-2169000	Unavailable	Source 2012-01-01 – 2012-12-31: 1086000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -1560000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -2169000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -2389000 USD Inspect Operating Cash Flow Open source
2013 2013-01-01 – 2013-12-31	1404000	2760000 Derived	-1356000	1075000 Derived	-2431000	227000 Derived	Source 2013-01-01 – 2013-12-31: 1404000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -1356000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -2431000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: 228000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 1000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	5414000	7048000 Derived	-1634000	9850000 Derived	-11484000	-933000 Derived	Source 2014-01-01 – 2014-12-31: 5414000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -1634000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -11484000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -714000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 219000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	849000	17779000 Derived	-16930000	-413000 Derived	-16517000	-12998000 Derived	Source 2015-01-01 – 2015-12-31: 849000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -16930000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -16517000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -12498000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 500000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	5527000	35177000 Derived	-29650000	-314000 Derived	-29336000	-27794000 Derived	Source 2016-01-01 – 2016-12-31: 5527000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -29650000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -29336000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -27370000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 424000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	3669000	69283000 Derived	-65614000	101000 Derived	-65715000	-54695000 Derived	Source 2017-01-01 – 2017-12-31: 3669000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -65614000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -65715000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -53177000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1518000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	3595000	78487000 Derived	-74892000	-729000 Derived	-74163000	-69231000 Derived	Source 2018-01-01 – 2018-12-31: 3595000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -74892000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -74163000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -68664000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 567000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	443000	96316000 Derived	-95873000	-695000 Derived	-95178000	-74452000 Derived	Source 2019-01-01 – 2019-12-31: 443000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -95873000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -95178000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -73394000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1058000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 443K 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	1086000	Revenue: 1086000 Open source
20132013-12-31	Revenue	1404000	Revenue: 1404000 Open source
20142014-12-31	Revenue	5414000	Revenue: 5414000 Open source
20152015-12-31	Revenue	849000	Revenue: 849000 Open source
20162016-12-31	Revenue	5527000	Revenue: 5527000 Open source
20172017-12-31	Revenue	3669000	Revenue: 3669000 Open source
20182018-12-31	Revenue	3595000	Revenue: 3595000 Open source
20192019-12-31	Revenue	443000	Revenue: 443000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-87.7% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	No prior comparable period	Revenue: 1086000 Open source
20132013-12-31	Year over year	29.3%	Revenue: 1404000 Open source Revenue: 1086000 Open source
20142014-12-31	Year over year	285.6%	Revenue: 5414000 Open source Revenue: 1404000 Open source
20152015-12-31	Year over year	-84.3%	Revenue: 849000 Open source Revenue: 5414000 Open source
20162016-12-31	Year over year	551%	Revenue: 5527000 Open source Revenue: 849000 Open source
20172017-12-31	Year over year	-33.6%	Revenue: 3669000 Open source Revenue: 5527000 Open source
20182018-12-31	Year over year	-2%	Revenue: 3595000 Open source Revenue: 3669000 Open source
20192019-12-31	Year over year	-87.7%	Revenue: 443000 Open source Revenue: 3595000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -21,641.8% 2019

Net margin -21,484.9% 2019

Free cash flow margin -16,806.3% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Operating margin	-143.6%	Operating Income: -1560000 Open source Revenue: 1086000 Open source
20132013-12-31	Operating margin	-96.6%	Operating Income: -1356000 Open source Revenue: 1404000 Open source
20142014-12-31	Operating margin	-30.2%	Operating Income: -1634000 Open source Revenue: 5414000 Open source
20152015-12-31	Operating margin	-1,994.1%	Operating Income: -16930000 Open source Revenue: 849000 Open source
20162016-12-31	Operating margin	-536.5%	Operating Income: -29650000 Open source Revenue: 5527000 Open source
20172017-12-31	Operating margin	-1,788.3%	Operating Income: -65614000 Open source Revenue: 3669000 Open source
20182018-12-31	Operating margin	-2,083.2%	Operating Income: -74892000 Open source Revenue: 3595000 Open source
20192019-12-31	Operating margin	-21,641.8%	Operating Income: -95873000 Open source Revenue: 443000 Open source
20122012-12-31	Net margin	-199.7%	Net Income: -2169000 Open source Revenue: 1086000 Open source
20132013-12-31	Net margin	-173.1%	Net Income: -2431000 Open source Revenue: 1404000 Open source
20142014-12-31	Net margin	-212.1%	Net Income: -11484000 Open source Revenue: 5414000 Open source
20152015-12-31	Net margin	-1,945.5%	Net Income: -16517000 Open source Revenue: 849000 Open source
20162016-12-31	Net margin	-530.8%	Net Income: -29336000 Open source Revenue: 5527000 Open source
20172017-12-31	Net margin	-1,791.1%	Net Income: -65715000 Open source Revenue: 3669000 Open source
20182018-12-31	Net margin	-2,062.9%	Net Income: -74163000 Open source Revenue: 3595000 Open source
20192019-12-31	Net margin	-21,484.9%	Net Income: -95178000 Open source Revenue: 443000 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 1086000 Open source Operating Cash Flow: -2389000 Open source
20132013-12-31	Free cash flow margin	16.2%	Revenue: 1404000 Open source Operating Cash Flow: 228000 Open source Capital Expenditure: 1000 Open source
20142014-12-31	Free cash flow margin	-17.2%	Revenue: 5414000 Open source Operating Cash Flow: -714000 Open source Capital Expenditure: 219000 Open source
20152015-12-31	Free cash flow margin	-1,531%	Revenue: 849000 Open source Operating Cash Flow: -12498000 Open source Capital Expenditure: 500000 Open source
20162016-12-31	Free cash flow margin	-502.9%	Revenue: 5527000 Open source Operating Cash Flow: -27370000 Open source Capital Expenditure: 424000 Open source
20172017-12-31	Free cash flow margin	-1,490.7%	Revenue: 3669000 Open source Operating Cash Flow: -53177000 Open source Capital Expenditure: 1518000 Open source
20182018-12-31	Free cash flow margin	-1,925.8%	Revenue: 3595000 Open source Operating Cash Flow: -68664000 Open source Capital Expenditure: 567000 Open source
20192019-12-31	Free cash flow margin	-16,806.3%	Revenue: 443000 Open source Operating Cash Flow: -73394000 Open source Capital Expenditure: 1058000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -73.4M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	-2389000	Operating Cash Flow: -2389000 Open source
20132013-12-31	Operating cash flow	228000	Operating Cash Flow: 228000 Open source
20142014-12-31	Operating cash flow	-714000	Operating Cash Flow: -714000 Open source
20152015-12-31	Operating cash flow	-12498000	Operating Cash Flow: -12498000 Open source
20162016-12-31	Operating cash flow	-27370000	Operating Cash Flow: -27370000 Open source
20172017-12-31	Operating cash flow	-53177000	Operating Cash Flow: -53177000 Open source
20182018-12-31	Operating cash flow	-68664000	Operating Cash Flow: -68664000 Open source
20192019-12-31	Operating cash flow	-73394000	Operating Cash Flow: -73394000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -74.5M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	Unavailable	Operating Cash Flow: -2389000 Open source
20132013-12-31	Free cash flow	227000	Operating Cash Flow: 228000 Open source Capital Expenditure: 1000 Open source
20142014-12-31	Free cash flow	-933000	Operating Cash Flow: -714000 Open source Capital Expenditure: 219000 Open source
20152015-12-31	Free cash flow	-12998000	Operating Cash Flow: -12498000 Open source Capital Expenditure: 500000 Open source
20162016-12-31	Free cash flow	-27794000	Operating Cash Flow: -27370000 Open source Capital Expenditure: 424000 Open source
20172017-12-31	Free cash flow	-54695000	Operating Cash Flow: -53177000 Open source Capital Expenditure: 1518000 Open source
20182018-12-31	Free cash flow	-69231000	Operating Cash Flow: -68664000 Open source Capital Expenditure: 567000 Open source
20192019-12-31	Free cash flow	-74452000	Operating Cash Flow: -73394000 Open source Capital Expenditure: 1058000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

78.3% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Liabilities / assets	Not reported	No source recorded
20132013-12-31	Liabilities / assets	216.1%	Total Liabilities: 6668000 Open source Total Assets: 3086000 Open source
20142014-12-31	Liabilities / assets	4.9%	Total Liabilities: 2515000 Open source Total Assets: 51277000 Open source
20152015-12-31	Liabilities / assets	4.2%	Total Liabilities: 4443000 Open source Total Assets: 105245000 Open source
20162016-12-31	Liabilities / assets	4.2%	Total Liabilities: 5650000 Open source Total Assets: 135635000 Open source
20172017-12-31	Liabilities / assets	14.5%	Total Liabilities: 11653000 Open source Total Assets: 80254000 Open source
20182018-12-31	Liabilities / assets	11.1%	Total Liabilities: 11549000 Open source Total Assets: 103731000 Open source
20192019-12-31	Liabilities / assets	78.3%	Total Liabilities: 63584000 Open source Total Assets: 81159000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.61× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Current assets / current liabilities	Not reported	No source recorded
20132013-12-31	Current assets / current liabilities	1.65×	Current Assets: 2895000 Open source Current Liabilities: 1751000 Open source
20142014-12-31	Current assets / current liabilities	23.85×	Current Assets: 50891000 Open source Current Liabilities: 2134000 Open source
20152015-12-31	Current assets / current liabilities	14.08×	Current Assets: 57149000 Open source Current Liabilities: 4058000 Open source
20162016-12-31	Current assets / current liabilities	22.2×	Current Assets: 117001000 Open source Current Liabilities: 5271000 Open source
20172017-12-31	Current assets / current liabilities	6.8×	Current Assets: 69504000 Open source Current Liabilities: 10228000 Open source
20182018-12-31	Current assets / current liabilities	9.66×	Current Assets: 101167000 Open source Current Liabilities: 10468000 Open source
20192019-12-31	Current assets / current liabilities	2.61×	Current Assets: 76414000 Open source Current Liabilities: 29326000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 2.17 million Exact value Exact value: -2169000 USD 2012-01-01 – 2012-12-31: -2169000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2012-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -2169000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2169000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891315000890/fomx-20141231.xml#401173 Filing: 000117891315000890 The citation records this snapshot. The page link may show a newer release later.	−USD 2.39 million Exact value Exact value: -2389000 USD 2012-01-01 – 2012-12-31: -2389000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2012-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: -2389000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2389000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891315000890/fomx-20141231.xml#1264664 Filing: 000117891315000890 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2013 2013-01-01 – 2013-12-31	−USD 2.43 million Exact value Exact value: -2431000 USD 2013-01-01 – 2013-12-31: -2431000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2013-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -2431000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2431000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891316004594/fomx-20151231.xml#143192 Filing: 000117891316004594 The citation records this snapshot. The page link may show a newer release later.	USD 228,000 Exact value Exact value: 228000 USD 2013-01-01 – 2013-12-31: 228000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2013-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: 228000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 228000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891316004594/fomx-20151231.xml#147977 Filing: 000117891316004594 The citation records this snapshot. The page link may show a newer release later.	USD 1,000 Exact value Exact value: 1000 USD 2013-01-01 – 2013-12-31: 1000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Foamix Pharmaceuticals Ltd. · 2013-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Capital Expenditure: 1000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891316004594/fomx-20151231.xml#148401 Filing: 000117891316004594 The citation records this snapshot. The page link may show a newer release later.	USD 227,000 Calculation and evidence 228000 − 1000 USD Exact free cash flow: 227000 USD 2013-01-01 – 2013-12-31: 228000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 1000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Foamix Pharmaceuticals Ltd. · 2013-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Free cash flow: 227000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 228000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891316004594/fomx-20151231.xml#147977 Filing: 000117891316004594 Input fundies:CapitalExpenditure: 1000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891316004594/fomx-20151231.xml#148401 Filing: 000117891316004594 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 11.48 million Exact value Exact value: -11484000 USD 2014-01-01 – 2014-12-31: -11484000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2014-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -11484000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11484000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891317000582/fomx-20161231.xml#157173 Filing: 000117891317000582 The citation records this snapshot. The page link may show a newer release later.	−USD 714,000 Exact value Exact value: -714000 USD 2014-01-01 – 2014-12-31: -714000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2014-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: -714000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -714000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891317000582/fomx-20161231.xml#166289 Filing: 000117891317000582 The citation records this snapshot. The page link may show a newer release later.	USD 219,000 Exact value Exact value: 219000 USD 2014-01-01 – 2014-12-31: 219000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Foamix Pharmaceuticals Ltd. · 2014-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Capital Expenditure: 219000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 219000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891317000582/fomx-20161231.xml#166923 Filing: 000117891317000582 The citation records this snapshot. The page link may show a newer release later.	−USD 933,000 Calculation and evidence -714000 − 219000 USD Exact free cash flow: -933000 USD 2014-01-01 – 2014-12-31: -714000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 219000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Foamix Pharmaceuticals Ltd. · 2014-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Free cash flow: -933000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -714000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891317000582/fomx-20161231.xml#166289 Filing: 000117891317000582 Input fundies:CapitalExpenditure: 219000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891317000582/fomx-20161231.xml#166923 Filing: 000117891317000582 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 16.52 million Exact value Exact value: -16517000 USD 2015-01-01 – 2015-12-31: -16517000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2015-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -16517000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16517000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891318000738/fomx-20171231.xml#143892 Filing: 000117891318000738 The citation records this snapshot. The page link may show a newer release later.	−USD 12.5 million Exact value Exact value: -12498000 USD 2015-01-01 – 2015-12-31: -12498000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2015-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: -12498000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12498000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891318000738/fomx-20171231.xml#329051 Filing: 000117891318000738 The citation records this snapshot. The page link may show a newer release later.	USD 500,000 Exact value Exact value: 500000 USD 2015-01-01 – 2015-12-31: 500000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Foamix Pharmaceuticals Ltd. · 2015-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Capital Expenditure: 500000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 500000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891318000738/fomx-20171231.xml#154351 Filing: 000117891318000738 The citation records this snapshot. The page link may show a newer release later.	−USD 13 million Calculation and evidence -12498000 − 500000 USD Exact free cash flow: -12998000 USD 2015-01-01 – 2015-12-31: -12498000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 500000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Foamix Pharmaceuticals Ltd. · 2015-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Free cash flow: -12998000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12498000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891318000738/fomx-20171231.xml#329051 Filing: 000117891318000738 Input fundies:CapitalExpenditure: 500000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891318000738/fomx-20171231.xml#154351 Filing: 000117891318000738 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 29.34 million Exact value Exact value: -29336000 USD 2016-01-01 – 2016-12-31: -29336000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2016-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -29336000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29336000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891319000725/fomx-20181231.xml#277440 Filing: 000117891319000725 The citation records this snapshot. The page link may show a newer release later.	−USD 27.37 million Exact value Exact value: -27370000 USD 2016-01-01 – 2016-12-31: -27370000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2016-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: -27370000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27370000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891319000725/fomx-20181231.xml#261081 Filing: 000117891319000725 The citation records this snapshot. The page link may show a newer release later.	USD 424,000 Exact value Exact value: 424000 USD 2016-01-01 – 2016-12-31: 424000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Foamix Pharmaceuticals Ltd. · 2016-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Capital Expenditure: 424000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 424000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891319000725/fomx-20181231.xml#142174 Filing: 000117891319000725 The citation records this snapshot. The page link may show a newer release later.	−USD 27.79 million Calculation and evidence -27370000 − 424000 USD Exact free cash flow: -27794000 USD 2016-01-01 – 2016-12-31: -27370000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 424000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Foamix Pharmaceuticals Ltd. · 2016-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Free cash flow: -27794000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27370000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891319000725/fomx-20181231.xml#261081 Filing: 000117891319000725 Input fundies:CapitalExpenditure: 424000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891319000725/fomx-20181231.xml#142174 Filing: 000117891319000725 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 65.72 million Exact value Exact value: -65715000 USD 2017-01-01 – 2017-12-31: -65715000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2017-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -65715000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65715000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#244408 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	−USD 53.18 million Exact value Exact value: -53177000 USD 2017-01-01 – 2017-12-31: -53177000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2017-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: -53177000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -53177000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#227746 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	USD 1.52 million Exact value Exact value: 1518000 USD 2017-01-01 – 2017-12-31: 1518000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Foamix Pharmaceuticals Ltd. · 2017-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Capital Expenditure: 1518000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1518000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133503 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	−USD 54.7 million Calculation and evidence -53177000 − 1518000 USD Exact free cash flow: -54695000 USD 2017-01-01 – 2017-12-31: -53177000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1518000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Foamix Pharmaceuticals Ltd. · 2017-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Free cash flow: -54695000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -53177000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#227746 Filing: 000117891320000792 Input fundies:CapitalExpenditure: 1518000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133503 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 74.16 million Exact value Exact value: -74163000 USD 2018-01-01 – 2018-12-31: -74163000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2018-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -74163000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74163000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#244537 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	−USD 68.66 million Exact value Exact value: -68664000 USD 2018-01-01 – 2018-12-31: -68664000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2018-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: -68664000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -68664000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#227933 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	USD 567,000 Exact value Exact value: 567000 USD 2018-01-01 – 2018-12-31: 567000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Foamix Pharmaceuticals Ltd. · 2018-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Capital Expenditure: 567000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 567000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133688 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	−USD 69.23 million Calculation and evidence -68664000 − 567000 USD Exact free cash flow: -69231000 USD 2018-01-01 – 2018-12-31: -68664000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 567000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Foamix Pharmaceuticals Ltd. · 2018-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Free cash flow: -69231000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -68664000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#227933 Filing: 000117891320000792 Input fundies:CapitalExpenditure: 567000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133688 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 95.18 million Exact value Exact value: -95178000 USD 2019-01-01 – 2019-12-31: -95178000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Net Income: -95178000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -95178000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#244666 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	−USD 73.39 million Exact value Exact value: -73394000 USD 2019-01-01 – 2019-12-31: -73394000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Operating Cash Flow: -73394000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -73394000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#228120 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	USD 1.06 million Exact value Exact value: 1058000 USD 2019-01-01 – 2019-12-31: 1058000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Capital Expenditure: 1058000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1058000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133872 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.	−USD 74.45 million Calculation and evidence -73394000 − 1058000 USD Exact free cash flow: -74452000 USD 2019-01-01 – 2019-12-31: -73394000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1058000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Foamix Pharmaceuticals Ltd. · 2019-12-31 Foamix Pharmaceuticals Ltd. (edgar:1606645) Free cash flow: -74452000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1606645?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -73394000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#228120 Filing: 000117891320000792 Input fundies:CapitalExpenditure: 1058000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1606645/000117891320000792/fomx-20191231.xml#133872 Filing: 000117891320000792 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

56 filings · 1,065 latest values · 1,065 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001606645, 1606645, edgar:1606645

Also known as Foamix Ltd., Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation